Dusa pharmaceuticals inc (DUSA)
Income statement / Yearly
Dec'11Dec'10Dec'09
Product revenues

45,296

36,423

28,338

Cost of product revenues

6,921

6,419

6,007

GROSS MARGIN

38,374

30,003

22,331

Research and development

5,275

4,929

4,313

Marketing and sales

15,382

13,240

12,897

General and administrative

9,956

9,105

7,956

TOTAL OPERATING COSTS

30,614

27,276

25,167

INCOME FROM OPERATIONS

7,759

2,727

-2,835

Other income

46

226

290

(Loss) gain on change in fair value of warrants

-1,013

-390

-376

INCOME (LOSS) FROM CONTINUING OPERATIONS, BEFORE INCOME TAX BENEFIT

6,793

2,563

-2,921

Income tax benefit

-

-

-162

(LOSS) INCOME FROM CONTINUING OPERATIONS

6,793

2,563

-2,758

(LOSS) INCOME FROM DISCONTINUED OPERATIONS

526

139

250

NET (LOSS) INCOME

7,319

2,702

-2,508

CONTINUING OPERATIONS

0.28

0.11

-0.11

DISCONTINUED OPERATIONS

0.02

0.01

0.01

BASIC NET (LOSS) INCOME PER SHARE

0.30

0.11

-0.10

CONTINUING OPERATIONS

0.26

0.10

-0.11

DISCONTINUED OPERATIONS

0.02

0.01

0.01

DILUTED NET (LOSS) INCOME PER SHARE

0.28

0.11

-0.10

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING, BASIC

24,531

24,188

24,102

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING, DILUTED

26,352

24,765

24,134